What is Wedbush’s Forecast for Vor Biopharma Q4 Earnings?

Vor Biopharma Inc. (NASDAQ:VOR) – Wedbush issued their Q4 2025 earnings per share (EPS) estimates for Vor Biopharma in a research note issued on Tuesday, November 25th. Wedbush analyst M. Fan forecasts that the company will post earnings of ($1.11) per share for the quarter. Wedbush currently has a “Neutral” rating on the stock. Wedbush also issued estimates for Vor Biopharma’s Q1 2026 earnings at ($1.25) EPS, Q2 2026 earnings at ($1.43) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at ($4.52) EPS, FY2027 earnings at ($9.16) EPS, FY2028 earnings at ($5.74) EPS and FY2029 earnings at ($4.43) EPS.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($3.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.06) by ($0.27).

A number of other brokerages also recently commented on VOR. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research note on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. Robert W. Baird upgraded Vor Biopharma from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $20.00 to $64.00 in a report on Wednesday, October 15th. Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Finally, Zacks Research raised Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $73.17.

Vor Biopharma Stock Performance

Shares of NASDAQ:VOR opened at $8.34 on Thursday. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80. The firm has a 50 day moving average price of $23.81. The stock has a market cap of $86.81 million, a P/E ratio of -0.02 and a beta of 2.02.

Insider Activity

In other news, major shareholder Reprogrammed Interchange Llc sold 447,278 shares of the firm’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $1.54, for a total value of $688,808.12. Following the completion of the sale, the insider owned 32,781,209 shares in the company, valued at approximately $50,483,061.86. This trade represents a 1.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. sold 260,859 shares of the business’s stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $29.39, for a total transaction of $7,666,646.01. Following the transaction, the director owned 15,104 shares in the company, valued at approximately $443,906.56. This trade represents a 94.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 2,327,243 shares of company stock worth $57,827,859 in the last 90 days. 0.45% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Vor Biopharma

A number of large investors have recently modified their holdings of VOR. OMERS ADMINISTRATION Corp acquired a new stake in shares of Vor Biopharma in the 1st quarter valued at approximately $100,000. Goldman Sachs Group Inc. raised its position in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. Jane Street Group LLC acquired a new stake in Vor Biopharma in the first quarter valued at $140,000. XTX Topco Ltd acquired a new stake in Vor Biopharma in the second quarter valued at $66,000. Finally, Ariose Capital Management Ltd purchased a new stake in shares of Vor Biopharma during the 3rd quarter worth $5,368,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.